Optic Neuritis: When is it just ON and when does it mean more?
December 12, 2019
Amanda D Henderson, MD
Wilmer Eye Institute at the Johns Hopkins University School of Medicine
Dr. Henderson is an Assistant Professor in Ophthalmology at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine in Baltimore, Maryland. She attended medical school at Emory University, completed a Residency in Ophthalmology at the Medical College of Georgia, and completed a Fellowship in Neuro-Ophthalmology at the Bascom Palmer Eye Institute. In addition to her work as a clinician, she is involved in clinical and translational research, with particular interests in optic neuropathies and in ophthalmic and neuro-imaging. She has presented nationally and internationally and published in these areas. She also has a particular interest in resident and medical student education, serving as the Fellowship Director for Neuro-Ophthalmology and the Education Champion for the Division of Neuro-Ophthalmology at Wilmer and on education-related committees in the American Academy of Ophthalmology (AAO) and the North American Neuro-Ophthalmology Society (NANOS), and is the recipient of the Helen Iliff Scholar Fund to support development of resident education.
Elias Sotirchos, MD
Johns Hopkins Neuromyelitis Optica Center
Dr. Sotirchos is a neurologist and Director of the Johns Hopkins Neuromyelitis Optica Center. He earned his medical degree from the National and Kapodistrian University of Athens and completed his neurology residency training at the Johns Hopkins Hospital. He subsequently pursued fellowship training in neuroimmunology at the Johns Hopkins Hospital as a National Multiple Sclerosis Society Sylvia Lawry Fellow. His research focuses on the application of imaging techniques, including retinal optical coherence tomography (OCT) and brain magnetic resonance imaging (MRI), to study multiple sclerosis (MS), neuromyelitis optica (NMO), and other neuroimmunological conditions. His work especially focuses on visual pathway involvement in these conditions, and aims to characterize mechanisms of neurodegeneration and to identify novel biomarkers for predicting and monitoring the disease course and therapeutic response.
SRNA Ask the Expert Podcast Series sponsored in part by
Alexion is a global biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Their goal is to deliver medical breakthroughs where none currently exist, and they are committed to ensuring that patient perspective and community engagement is always at the forefront of their work.
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit https://www.gene.com.
Viela Bio is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Their team is comprised of passionate, talented, world-class leaders with diverse experience in the autoimmune disease space, and their research focuses on well-established critical biological pathways shared across multiple indications.
* The Executive Committee of SRNA with the medical and scientific council determines the content and topics of the podcasts. Sponsors are not able to influence the education program.